For decades, medicine has relied on the same core delivery formats: pills, liquids, and injections. But a new generation of founders is questioning that status quo—not with incremental tweaks, but with entirely new formats.
At the forefront of that shift are Aviraj, Dhilen, and Brijen Soin, the teenage co-founders of Soin Pharmaceuticals, who are developing Oral Thin Film (OTF) technology—a rapidly emerging platform that transforms how medications and supplements are delivered.
Their idea is simple but powerful: replace the pill with a dissolvable strip.
Rethinking the Last Mile of Medicine
Oral Thin Film is exactly what it sounds like—a small, rectangular strip placed on the tongue that dissolves within seconds, delivering active compounds through the oral mucosa.
It's a subtle shift in form factor, but a meaningful one.
Instead of:
- Swallowing tablets
- Measuring liquids
- Scheduling injections
Patients can take a precisely dosed strip—no water, no discomfort, no friction.
For the Soin brothers, that simplicity is the point.
"People underestimate how inconvenient pills really are until you try to redesign the experience," says Dhilen Soin. "With oral thin film, it's easier—you place it on your tongue, and you're done."
Innovation Rooted in Personal Experience
For Aviraj Soin, the motivation behind OTF isn't theoretical—it's lived.
"I've been dealing with allergies for years, and the routine of weekly shots gets old fast," he explains. "We started asking why there isn't a simpler, daily alternative—something you can just take without needles."
That question became the foundation for Soin Pharmaceuticals' approach: designing drug delivery systems that prioritize patient experience as much as pharmacology.
The result is a platform that could extend far beyond allergy care—into vitamins, dental health, and eventually more complex therapeutics. The OTF is still investigational, and larger stage clinical trials to prove their theory are still needed.
Young Builders, Not Just Students
The Soin brothers' trajectory doesn't follow a traditional path.
Before entering the pharmaceutical space, they were already inventors—filing patents for:
- A bioluminescent tornado simulation toy
- A GPS-based object tracking system
During the COVID-19 lockdowns, they expanded into cryptocurrency mining, building automated systems and using the proceeds to fund early-stage innovation. What might have been a distraction became a crash course in systems thinking, capital allocation, and startup execution.
Now, as students at Stanford Online High School, they are simultaneously advancing academic research and product development—an unusual but increasingly relevant combination in a world where technical fluency starts early.
From Lab Bench to Scalable Platform
Working alongside experienced researchers and industry partners, the brothers have already contributed to:
- Topical pain formulations currently progressing through regulatory pathways
- Exploration of plant-based anti-inflammatory compounds
- Development of oral thin film formats for nutraceutical and dental applications
Their academic output is equally notable. Over four summers, Aviraj and Dhilen have each served as first author on twelve peer-reviewed abstracts, presented at major pain medicine conferences across the Midwest.
But for Soin Pharmaceuticals, research is just the starting point.
The larger ambition is to turn Oral Thin Film into a scalable delivery platform—one that can be adapted across multiple therapeutic categories.
Designing for Compliance in a Frictionless World
One of healthcare's most persistent problems is adherence: patients often don't take medications as prescribed, not because they don't want to—but because the process is inconvenient.
The Soin brothers see OTF as a direct response to that challenge.
"If you make something easier, people actually use it," says Dhilen. "That's true whether you're building software or healthcare products."
By eliminating barriers—no swallowing, no measuring, no injections—Oral Thin Film has the potential to improve compliance at scale.
What the Soin Brothers Represent
Soin Pharmaceuticals is more than a startup—it's a signal.
It reflects a broader shift toward:
- User-centered healthcare design
- Platform-based drug delivery systems
- Younger founders entering highly technical industries earlier than ever
For Aviraj, the mission remains grounded in simplicity:
"At the end of the day, we're trying to make taking medicine as easy as possible. If we can replace even a fraction of injections or pills with something simpler, that's a win."
As Oral Thin Film technology continues to gain traction, the Soin brothers are positioning themselves not just as participants—but as early architects of what could become a new standard.
In their view, the future of medicine doesn't just work better.
It dissolves.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission.
